A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Trial Profile

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Sitravatinib (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors MethylGene; Mirati Therapeutics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 Mar 2017 According to a Mirati Therapeutics media release, the Company expects to provide an update on efficacy data in the third quarter of 2017.
    • 05 Jan 2017 Results (data cut-off of December 9, 2016) published in a Mirati Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top